Alongside its US expansion, Cellomatics is looking to consolidate its presence in Europe and has welcomed Dr Pier Giorgio Amendola to support with the company’s business development efforts.
A key challenge for UK-based CROs operating internationally is managing cultural differences and regional market dynamics. Due to his extensive experience in working across various European countries, including Israel, Spain, Denmark and the Netherlands, Pier is well equipped to navigate these challenges and to build strong local partnerships. He will be focused on identifying new business opportunities, building and nurturing relationships with key stakeholders, and enhancing Cellomatics’ market footprint.
Pier holds a PhD in Molecular Mechanisms of Disease and has taken on leadership roles in both small biotech firms and established pharmaceutical companies throughout his career. These include positions such as Research Director at ONA Therapeutics and Associate Director of the Discovery Biology Unit at Dompé Farmaceutici. His professional journey encapsulates his passion for innovation and commitment to patient care and has provided him with extensive experience in drug development, particularly within the areas of oncology and immunology.
Of joining Cellomatics, Pier says, “Cellomatics provides a dynamic, science-driven environment that allows for close collaboration with clients and the delivery of tailored, innovative solutions. Having been a client of Cellomatics in my previous roles, I value its high scientific standards and am eager to promote its capabilities to new clients, accelerating their drug development pipelines.”
Cellomatics CEO and founder, Shailendra Singh comments: “Having worked with Pier for a number of years through Dompé we are delighted that he has decided to join the Cellomatics team in a Business Development role.
“His experience working in the pharmaceutical sector has given him a deep understanding of our client needs and this will be key in building new relationships and achieving Cellomatics’ growth goals.”
Cellomatics aims to establish a strong presence in the European market by leveraging its expertise in innovative preclinical in vitro bioassay services. Pier will be vital to achieving this success as he will ensure the company builds strong relationships with key stakeholders, positioning Cellomatics as a trusted partner to accelerate clients’ drug development programs.
Keep an eye on our news page to see the latest news and updates as we continue our European expansion and further development of Cellomatics.
